IgE Antibodies: From Structure to Function and Clinical Translation

Area of Science:

• Immunology and Structural Biology
• Cancer Immunotherapy
• Antibody Engineering

Background:

• Immunoglobulin E (IgE) antibodies mediate allergic reactions via Fc receptors (FcεRI, FcεRII/CD23).
• Structural studies reveal IgE-Fc conformation flexibility and allosteric receptor interactions.
• IgE's high affinity for FcεRI on tumor-infiltrating immune cells and lack of inhibitory receptors offer unique anti-cancer potential.

Purpose of the Study:

• To explore the potential of IgE antibodies in cancer immunotherapy.
• To investigate the structural basis of IgE-Fc interactions with its receptors.
• To evaluate the efficacy and safety of IgE-based cancer therapies.

Main Methods:

• Structural analysis of IgE-Fc alone and complexed with receptors and antibodies.
• In vitro and in vivo evaluations of IgE immunotherapy efficacy against solid tumors.
• Ex vivo and in vivo safety assessments of anti-cancer IgE antibodies.

Main Results:

• IgE-Fc exhibits conformational flexibility critical for function and therapeutic targeting.
• Tumor antigen-specific IgE antibodies demonstrate enhanced anti-cancer immune profiles.
• Proof-of-concept studies show promising efficacy and safety for IgE immunotherapies.

Conclusions:

• Understanding IgE structure-function relationships is key to developing novel cancer immunotherapies.
• IgE antibodies represent a promising therapeutic modality for solid tumors.
• The first anti-cancer IgE antibody, MOv18, has entered clinical trials, validating this approach.